Salzman E W
Adv Exp Med Biol. 1978;102:265-83. doi: 10.1007/978-1-4757-1217-9_18.
Platelet aggregates are important in the thromboembolic complications of prosthetic devices, and drugs that alter platelet function have shown promise in clinical trials. Results with these drugs have increased insight into the interaction of platelets with artificial materials, particularly when the clinical experience has been correlated with the results of in vitro models. In a bead column/surface contact model, the characteristic interactions of platelets with artificial surfaces resemble effects of adding thrombin ADP to platelet-rich plasma. Anti-inflammatory agents and other antiplatelet drugs inhibit these reactions. Results in an in vivo model, survival of 51 Cr-labeled platelets in sheep bearing arteriovenous shunts of test materials, correlate systems indicate that the initial events upon contact of a surface with plasma proteins persistently influence the long-term behavior of that surface toward blood. A review of clinical studies discusses the effect of antiplatelet drugs on platelet survival and also on thrombotic complications of heart valve replacement and other conditions employing prosthetic devices.
血小板聚集体在人工装置的血栓栓塞并发症中起重要作用，而改变血小板功能的药物在临床试验中已显示出前景。这些药物的研究结果加深了人们对血小板与人工材料相互作用的理解，尤其是当临床经验与体外模型的结果相关联时。在珠柱/表面接触模型中，血小板与人工表面的特征性相互作用类似于向富含血小板血浆中添加凝血酶和二磷酸腺苷（ADP）的效果。抗炎药和其他抗血小板药物可抑制这些反应。在体内模型中，在植入测试材料动静脉分流器的绵羊体内51铬标记血小板的存活情况表明，表面与血浆蛋白接触后的初始事件持续影响该表面对血液的长期行为。一项临床研究综述讨论了抗血小板药物对血小板存活的影响，以及对心脏瓣膜置换和其他使用人工装置的疾病的血栓形成并发症的影响。
